,8 In addition, SSA/Ps exhibit a high frequency of gain-of-function mutations in the BRAF gene, ranging from 70% to 100%9‐13; BRAF mutations have been implicated in a variety of cancers due to their activation of the MAPK signaling pathway.14 The gene discussed is BRAF; the disease is cancer.